Newsroom
July 1, 2021
Dr. Dimpy P. Shah, Population Health Sciences/Mays Cancer Center, was included within a story in Yahoo addressing her research in which 94% of the 131 patients in the study produced antibodies three to four weeks after full vaccination, most of which had solid cancers as opposed to cancers in the blood. Read story
July 1, 2021
In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact that a small group of the patients exhibited no response raised questions about how their protection against the virus will be addressed moving forward.
June 30, 2021
Small subsets of high-risk patients produce few or no antibodies, however. Contact: Will Sansom, (210) 567-2579, sansom@uthscsa.edu SAN ANTONIO (June 30, 2021) — In a U.S. and Swiss study, nearly all patients with cancer developed good immune response to the COVID-19 mRNA vaccines three to four weeks after receiving their second dose, but the fact […]
June 28, 2021
Our biochemistry team learns more about how the coronavirus disguises itself in the body.
June 17, 2021
Dr. Jason Bowling, Infectious Diseases, and Dr. Ruth Berggren, Infectious Diseases/Center for Medical Humanities and Ethics, spoke to the San Antonio Express-News about the Delta coronavirus variant being a threat to the unvaccinated, partially vaccinated San Antonians (subscription needed). Read the story.
June 17, 2021
(Editor’s note: This story, originally posted on Feb. 11, 2021, has been updated to include the study’s publication in JAMA Oncology on June 17, 2021.) Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 17, 2021) — Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. […]
